The COVID-19 pandemic has prompted numerous research institutes and companies to develop vaccine candidates targeting this novel disease.This tracker was developed by the Vaccine Centre at the London School of Hygiene & Tropical Medicine to follow candidates as they progress through the development pipeline.

Last updated onWe currently update the vaccine landscape weekly, pooling the latest information from the WHO, the Milken Institute and clinicaltrials.gov. We are also grateful for additional information provided directly by vaccine developers.For a copy of the database, or to inform us of a candidate that is not included, please contact vaccines@lshtm.ac.uk.

Last updated onEach week, we search clinicaltrials.gov for studies of COVID-19 vaccine candidates and extract key attributes from the registered protocols. Additional trials are identified using the WHO COVID-19 vaccine landscape. Trials are listed by decreasing size.

aAPC: artificial antigen presenting cell; AZLB: Anhui Zhifei Longcom Biopharmaceutical; BIBP: Beijing Institute of Biological Products; BWBP: Beijing Wantai Biological Pharmacy; CAMS: Chinese Academy of Medical Sciences; FBRI SRC VB: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology; KBP: Kentucky BioProcessing; LV-SMENP-DC: vaccine comprising dendritic cells (DCs) modified with lentivirus (LV) vectors expressing 'SMENP' minigene; PLA-AMS: People's Liberation Army Academy of Military Science; SGMI: Shenzhen Geno-Immune Medical Institute; WIBP: Wuhan Institute of Biological Products.